Paracetamol CSF Pharmacokinetics Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite its use for decades all over the world, the exact mechanism of action of paracetamol is not fully understood and essentially involves a combination of hypotheses. It is known to have an effect via the central nervous system, and of the many mechanisms proposed, one hypothesis is that it may have indirectly activate CB1 (cannabinoid) receptors, through its novel metabolite AM404.

This study aims to elucidate cerebrospinal levels of paracetamol and to measure the concentration of its metabolites, including AM404 in CSF. This may, in turn, give us useful information on the mechanism of action of paracetamol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Paracetamol and Pharmacogenetic

NCT01520792

Healthy

COMPLETED PHASE1

The Markers and Paracetamol Poisoning Study 2

NCT03497104

Paracetamol Overdose

COMPLETED

Pharmacokinetic Study of a Fixed Dose Combination Nefopam Hydrochloride (30 mg) / Paracetamol (500 mg)

NCT05129137

Healthy Volunteers

COMPLETED PHASE1

Detection of Paracetamol Concentration in Blood-, Saline- and Urine Samples - a Validation Study for a Novel Technique

NCT04690673

Drug Mechanism Healthy

COMPLETED NA

Impact of Naloxone on the Analgesic Effect of Paracetamol in Healthy Volunteers

NCT00750048

Pain

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients undergoing spinal blockade for urological surgery were administered 1g paracetamol intravenously at varying intervals prior to spinal anaesthesia, at which time 5mls of cerebrospinal fluid and 10mls of blood were sampled, and analysed for concentrations of paracetamol, paracetamol glucuronide, paracetamol sulphate, and AM404, a known endocannabinoid reuptake inhibitor, and metabolite of paracetamol.

Paracetamol readily penetrates into the cerebrospinal fluid in animal studies and in children. This could account for the rapid central analgesic and antipyretic action of intravenous paracetamol however this remains to be studied in adults. AM404 has never before been identified in humans, and its presence in CSF following paracetamol supports the hypothesis of a central mechanism of action of paracetamol via AM404.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paracetamol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sampling at approx 15 minutes

Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol

Group Type ACTIVE_COMPARATOR

Administration of paracetamol

Intervention Type DRUG

Administration of 1g intravenous paracetamol

Sampling at approx 30 minutes

Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol

Group Type ACTIVE_COMPARATOR

Administration of paracetamol

Intervention Type DRUG

Administration of 1g intravenous paracetamol

Sampling at approx 120minutes

Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol

Group Type ACTIVE_COMPARATOR

Administration of paracetamol

Intervention Type DRUG

Administration of 1g intravenous paracetamol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Administration of paracetamol

Administration of 1g intravenous paracetamol

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perfalgan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects aged 18 to 80 years
* Subjects undergoing surgery who require a spinal anaesthetic and paracetamol as part of their routine anaesthetic plan
* Subjects with an American Society of Anesthesiology score of I-III

Exclusion Criteria

* Subjects with any contraindication to spinal anaesthesia
* Subjects with known clotting abnormalities
* Pregnant or lactating women
* Subjects with known hypersensitivity to paracetamol
* Patients with severe hepatocellular insufficiency
* Patients already taking regular doses of paracetamol
* Any subjects deemed medically unsuitable by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No